PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-kappaB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer[1][2][3].
Molecular Weight:
538.56
Purity:
99.29
CAS Number:
[2083618-79-3]
Formula:
C28H26N8O4
Target:
EGFR,FAK,MMP,NF-kappaB,SDCBP
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
